Edgen Stock·Dec 19 2025, 08:41Back
AstraZeneca and Daiichi Sankyo Gain EU Review for DATROWAY Cancer Drug
Edgen Stock·Dec 19 2025, 08:41
[1] DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy (https://finance.yahoo.com/news/datroway-type- ...)
